Actively Recruiting
QuantaFlo HD Clinical Validation Study
Led by Semler Scientific · Updated on 2025-10-23
600
Participants Needed
1
Research Sites
44 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.
CONDITIONS
Official Title
QuantaFlo HD Clinical Validation Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female adult aged 22 years or older
- History of cardiovascular disease or peripheral artery disease (PAD)
- History of at least two of the following: hypertension, diabetes, or hyperlipidemia
You will not qualify if you...
- Unable to safely perform a forced expiration or obtain a technically adequate forced expiration test result
- Presence of a pacemaker or ICD with pacemaker function
- Terminal advanced illness
- Cardiothoracic surgery within the past 12 months
- Retinal eye disease with anticoagulant use
- Eye surgery within the last 90 days
- Uncontrolled hypertension with systolic pressure over 180 mmHg or diastolic pressure over 100 mmHg
- Severe tremors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pima Heart and Vascular
Tucson, Arizona, United States, 85741
Actively Recruiting
Research Team
G
Gena Parker
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here